TY - JOUR
T1 - Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET
AU - Schindler, Suzanne
AU - Li, Yan
AU - Buckles, Virginia
AU - Gordon, Brian
AU - Benzinger, Tammie L.S.
AU - Wang, Guoqiao
AU - Coble, Dean
AU - Klunk, William E.
AU - Fagan, Anne M.
AU - Holtzman, David M.
AU - Bateman, Randall J.
AU - Morris, John
AU - Xiong, Chengjie
N1 - Publisher Copyright:
© American Academy of Neurology.
PY - 2021/11/2
Y1 - 2021/11/2
N2 - Background and ObjectivesTo predict when cognitively normal individuals with brain amyloidosis will develop symptoms of Alzheimer disease (AD).MethodsBrain amyloid burden was measured by amyloid PET with Pittsburgh compound B. The mean cortical standardized uptake value ratio (SUVR) was transformed into a timescale with the use of longitudinal data.ResultsAmyloid accumulation was evaluated in 236 individuals who underwent >1 amyloid PET scan. The average age was 66.5 ± 9.2 years, and 12 individuals (5%) had cognitive impairment at their baseline amyloid PET scan. A tipping point in amyloid accumulation was identified at a low level of amyloid burden (SUVR 1.2), after which nearly all individuals accumulated amyloid at a relatively consistent rate until reaching a high level of amyloid burden (SUVR 3.0). The average time between levels of amyloid burden was used to estimate the age at which an individual reached SUVR 1.2. Longitudinal clinical diagnoses for 180 individuals were aligned by the estimated age at SUVR 1.2. In the 22 individuals who progressed from cognitively normal to a typical AD dementia syndrome, the estimated age at which an individual reached SUVR 1.2 predicted the age at symptom onset (R2 = 0.54, p < 0.0001, root mean square error [RMSE] 4.5 years); the model was more accurate after exclusion of 3 likely misdiagnoses (R2 = 0.84, p < 0.0001, RMSE 2.8 years).ConclusionThe age at symptom onset in sporadic AD is strongly correlated with the age at which an individual reaches a tipping point in amyloid accumulation.
AB - Background and ObjectivesTo predict when cognitively normal individuals with brain amyloidosis will develop symptoms of Alzheimer disease (AD).MethodsBrain amyloid burden was measured by amyloid PET with Pittsburgh compound B. The mean cortical standardized uptake value ratio (SUVR) was transformed into a timescale with the use of longitudinal data.ResultsAmyloid accumulation was evaluated in 236 individuals who underwent >1 amyloid PET scan. The average age was 66.5 ± 9.2 years, and 12 individuals (5%) had cognitive impairment at their baseline amyloid PET scan. A tipping point in amyloid accumulation was identified at a low level of amyloid burden (SUVR 1.2), after which nearly all individuals accumulated amyloid at a relatively consistent rate until reaching a high level of amyloid burden (SUVR 3.0). The average time between levels of amyloid burden was used to estimate the age at which an individual reached SUVR 1.2. Longitudinal clinical diagnoses for 180 individuals were aligned by the estimated age at SUVR 1.2. In the 22 individuals who progressed from cognitively normal to a typical AD dementia syndrome, the estimated age at which an individual reached SUVR 1.2 predicted the age at symptom onset (R2 = 0.54, p < 0.0001, root mean square error [RMSE] 4.5 years); the model was more accurate after exclusion of 3 likely misdiagnoses (R2 = 0.84, p < 0.0001, RMSE 2.8 years).ConclusionThe age at symptom onset in sporadic AD is strongly correlated with the age at which an individual reaches a tipping point in amyloid accumulation.
UR - http://www.scopus.com/inward/record.url?scp=85121406367&partnerID=8YFLogxK
U2 - 10.1212/WNL.0000000000012775
DO - 10.1212/WNL.0000000000012775
M3 - Article
C2 - 34504028
AN - SCOPUS:85121406367
SN - 0028-3878
VL - 97
SP - E1823-E1834
JO - Neurology
JF - Neurology
IS - 18
ER -